Treatment of advanced Hodgkin lymphomas in adolescents and young adults: efficacy and toxicity issues

Hodgkin’s lymphoma (HL) is highly sensitive to chemo- and radiotherapy. Long-term tumor-free survival in patients with early stages is close to 95–98 %. Therapy results in patients with advanced stages is worse that requires an intensification of treatment and creates the issuesof late toxicity prev...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu. V. Larina, S. V. Minenko, E. R. Biyachuev, A. V. Pshonkin, N. K. Khuazheva, V. V. Ptushkin
Format: Article
Language:Russian
Published: ABV-press 2014-07-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849409269571518464
author Yu. V. Larina
S. V. Minenko
E. R. Biyachuev
A. V. Pshonkin
N. K. Khuazheva
V. V. Ptushkin
author_facet Yu. V. Larina
S. V. Minenko
E. R. Biyachuev
A. V. Pshonkin
N. K. Khuazheva
V. V. Ptushkin
author_sort Yu. V. Larina
collection DOAJ
description Hodgkin’s lymphoma (HL) is highly sensitive to chemo- and radiotherapy. Long-term tumor-free survival in patients with early stages is close to 95–98 %. Therapy results in patients with advanced stages is worse that requires an intensification of treatment and creates the issuesof late toxicity prevention. These problems are especially relevant in young adults with a life expectancy of 40 years or more. Escalated BEACOPP protocol developed by the German study group allows to achieve cure the majority of patients with advanced-stage Hodgkin’s lymphoma, but this regime has significant toxicity. It causes infertility in almost all patients. BEACOPP-14 with comparable activity contains less cumulative doses of potentially gonadotoxic alkylating agents. Efficacy and toxicity of this regime has been analyzed in 29 patients with prognostically unfavorable stages of HL (m – 13, f – 16) received 8 courses BEACOPP-14 without a dose reduction of cytostatics. The median age of patients was 24 (20–35) years. With a median follow-up of 32.8 (4–66) months, event-free survival was 92.8 %, disease-free – 96.2 %, and overall survival – 95.2 %. Of the 16 women included in the study, the menstrual cycle was restored in 14 patients during 3–6 months. 2 patients were not evaluated because of switch to more intensive chemotherapy in the early stages of treatment. Of the remaining 14 patients pregnancy occurred in 3 (18.7 %), delivery – in 2, abortion – in 1. Delivery was term, children born healthy. Most of the patients according to the doctors’ recommendations protects and continues to avoid pregnancy for 2 years after treatment. The data indicate a potentially less reproductive damaging of BEACOPP-14 in females retaining high anti-tumor efficacy.
format Article
id doaj-art-7094ad1cb6ea4faf8d7af8b9687b551e
institution Kabale University
issn 1818-8346
2413-4023
language Russian
publishDate 2014-07-01
publisher ABV-press
record_format Article
series Онкогематология
spelling doaj-art-7094ad1cb6ea4faf8d7af8b9687b551e2025-08-20T03:35:33ZrusABV-pressОнкогематология1818-83462413-40232014-07-0191111810.17650/1818-8346-2014-9-1-11-1821Treatment of advanced Hodgkin lymphomas in adolescents and young adults: efficacy and toxicity issuesYu. V. Larina0S. V. Minenko1E. R. Biyachuev2A. V. Pshonkin3N. K. Khuazheva4V. V. Ptushkin5Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of RussiaFederal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of RussiaFederal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of RussiaFederal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of RussiaS. P. Botkin City Clinical Hospital, Moscow Healthcare DepartmentFederal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia N. I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaHodgkin’s lymphoma (HL) is highly sensitive to chemo- and radiotherapy. Long-term tumor-free survival in patients with early stages is close to 95–98 %. Therapy results in patients with advanced stages is worse that requires an intensification of treatment and creates the issuesof late toxicity prevention. These problems are especially relevant in young adults with a life expectancy of 40 years or more. Escalated BEACOPP protocol developed by the German study group allows to achieve cure the majority of patients with advanced-stage Hodgkin’s lymphoma, but this regime has significant toxicity. It causes infertility in almost all patients. BEACOPP-14 with comparable activity contains less cumulative doses of potentially gonadotoxic alkylating agents. Efficacy and toxicity of this regime has been analyzed in 29 patients with prognostically unfavorable stages of HL (m – 13, f – 16) received 8 courses BEACOPP-14 without a dose reduction of cytostatics. The median age of patients was 24 (20–35) years. With a median follow-up of 32.8 (4–66) months, event-free survival was 92.8 %, disease-free – 96.2 %, and overall survival – 95.2 %. Of the 16 women included in the study, the menstrual cycle was restored in 14 patients during 3–6 months. 2 patients were not evaluated because of switch to more intensive chemotherapy in the early stages of treatment. Of the remaining 14 patients pregnancy occurred in 3 (18.7 %), delivery – in 2, abortion – in 1. Delivery was term, children born healthy. Most of the patients according to the doctors’ recommendations protects and continues to avoid pregnancy for 2 years after treatment. The data indicate a potentially less reproductive damaging of BEACOPP-14 in females retaining high anti-tumor efficacy.https://oncohematology.abvpress.ru/ongm/article/view/6hodgkin’s lymphomachemotherapytoxicityreproductive functionbeacopp-14
spellingShingle Yu. V. Larina
S. V. Minenko
E. R. Biyachuev
A. V. Pshonkin
N. K. Khuazheva
V. V. Ptushkin
Treatment of advanced Hodgkin lymphomas in adolescents and young adults: efficacy and toxicity issues
Онкогематология
hodgkin’s lymphoma
chemotherapy
toxicity
reproductive function
beacopp-14
title Treatment of advanced Hodgkin lymphomas in adolescents and young adults: efficacy and toxicity issues
title_full Treatment of advanced Hodgkin lymphomas in adolescents and young adults: efficacy and toxicity issues
title_fullStr Treatment of advanced Hodgkin lymphomas in adolescents and young adults: efficacy and toxicity issues
title_full_unstemmed Treatment of advanced Hodgkin lymphomas in adolescents and young adults: efficacy and toxicity issues
title_short Treatment of advanced Hodgkin lymphomas in adolescents and young adults: efficacy and toxicity issues
title_sort treatment of advanced hodgkin lymphomas in adolescents and young adults efficacy and toxicity issues
topic hodgkin’s lymphoma
chemotherapy
toxicity
reproductive function
beacopp-14
url https://oncohematology.abvpress.ru/ongm/article/view/6
work_keys_str_mv AT yuvlarina treatmentofadvancedhodgkinlymphomasinadolescentsandyoungadultsefficacyandtoxicityissues
AT svminenko treatmentofadvancedhodgkinlymphomasinadolescentsandyoungadultsefficacyandtoxicityissues
AT erbiyachuev treatmentofadvancedhodgkinlymphomasinadolescentsandyoungadultsefficacyandtoxicityissues
AT avpshonkin treatmentofadvancedhodgkinlymphomasinadolescentsandyoungadultsefficacyandtoxicityissues
AT nkkhuazheva treatmentofadvancedhodgkinlymphomasinadolescentsandyoungadultsefficacyandtoxicityissues
AT vvptushkin treatmentofadvancedhodgkinlymphomasinadolescentsandyoungadultsefficacyandtoxicityissues